Bladder cancer
UPDATED --- First-line therapy of synchronous and metachronous metastatic UCa

Lucius (75 years old)

Lucius, a 75-year-old retired diplomat, hosts lively geopolitical debates with his friends. His passion for global affairs keeps his minds sharp and engaged.

He was diagnosed with urothelial muscle-invasive bladder cancer (MIBC) cT2N0M0. He underwent immediate radical cystectomy (RC) without receiving neoadjuvant chemotherapy. The pathological review of the RC specimen indicated pT3 pN0 (0/10) R0, PD-L1 negative. Following RC, the patient received 4 cycles of adjuvant gemcitabine + cisplatin, which was well tolerated.

He presents with liver metastases 5 months after completing adjuvant chemotherapy.

Assessment summary:

  • Former smoker (20 pack years)
  • No relevant medical history
  • ECOG PS: 1
  • Haemoglobin: 12.5 g/dl
  • Peripheral neuropathy: grade 1
  • No hearing impairment
  • GFR: 70 ml/min
  • CT scan reveals diffuse liver metastases, biopsy compatible with UCa
  • FGFR2/3 alteration status in metastatic biopsy specimen: activating FGFR3 mutation

Which of the following options would you choose for this patient?